Article
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2025
Besse Benjamin, Goto Koichi, Wang Yongsheng, Lee Se-Hoon, Marmarelis Melina E, Ohe Yuichiro, Bernabe Caro Reyes, Kim Dong-Wan, Lee Jong-Seok, Cousin Sophie, Ichihara Eiki, Li Yongsheng, Paz-Ares Luis, Ono Akira, Sanborn Rachel E, Watanabe Naohiro, de Miguel Maria Jose, Helissey Carole, Shu Catherine A, Spira Alexander I, Tomasini Pascale, Yang James Chih-Hsin, Zhang Yiping, Felip Enriqueta, Griesinger Frank, Waqar Saiama N, Calles Antonio, Neal Joel W, Baik Christina S, Jänne Pasi A, Shreeve S Martin, Curtin Joshua C, Patel Bharvin, Gormley Michael, Lyu Xuesong, Chen Jun, Chu Pei-Ling, Mahoney Janine, Trani Leonardo, Bauml Joshua M, Thayu Meena, Knoblauch Roland E, Cho Byoung Chul
Abstract excerpt
INTRODUCTION: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. METHODS: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy. Primary end point was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.